Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Benlysta® (belimumab) – Expanded indication
July 27, 2022 - GSK announced the FDA approval of Benlysta (belimumab), for the treatment of patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.
